Pangea Biomed is a technology company.
Pangea Biomed has raised $12.0M across 2 funding rounds.
Pangea Biomed has raised $12.0M in total across 2 funding rounds.
Pangea Biomed has raised $12.0M in total across 2 funding rounds.
Pangea Biomed's investors include NFX, Vital Capital.
Pangea Biomed is a Tel Aviv-based biotechnology company founded in 2018 that develops the ENLIGHT platform, the world's most advanced multi-cancer, multi-therapy response predictor for precision oncology.[1][2][4] ENLIGHT combines machine learning, deep RNA analysis, and "gene social networks" to map tumor molecular signatures—beyond just genomic mutations—and predict patient responses to over 100 targeted and immuno-oncology drugs across dozens of cancer types, increasing eligible patients by 5x compared to current methods (from <10% to over 50%).[1][2][6] It serves cancer patients, oncologists, and biopharma companies by enabling personalized treatment nominations, novel drug target identification, combination therapies, biomarker improvement for trials, and drug indication expansion; recent advancements like ENLIGHT-DP use deep learning on standard tumor pathology slides (H&E) to predict gene expression without costly sequencing, achieving comparable accuracy and real-world impact in saving advanced-stage patients.[2][3][5] The platform has analyzed over 2,300 patients across 40 cancer types and 25 drugs with an 80% success rate in identifying optimal treatments.[3]
Pangea Biomed emerged from the need to overcome precision oncology's limitations, where less than 10% of patients benefit from treatments despite decades of immunotherapy advances—one in six global deaths tied to cancer.[1][6] Co-founded in 2018 by experts like Eytan Ruppin (a computational biologist and fellow of the International Society for Computational Biology, with prior ventures in precision medicine like Metabomed and Medaware) and others focused on transcriptomics-based approaches, the company built ENLIGHT to analyze tumor "social graphs" of gene interactions using RNA data, epigenetics, and proteomics.[1][4][7] Early traction came from rigorous validations published in top journals like *Cell*, *Science Advances*, *Cancer Cell*, and *Nature Communications*, proving its edge over mutation-only methods; pivotal moments include the 2022 launch of ENLIGHT-DP in collaboration with the Australian National University and National Cancer Institute, enabling predictions from routine pathology slides and democratizing access in resource-limited settings.[2][5][8]
Pangea rides the AI-driven precision oncology wave, where machine learning meets multi-omics to shift from one-size-fits-all cancer care amid rising immunotherapy adoption and global cancer burden (1 in 6 deaths).[1][6] Timing aligns with digital pathology's maturity—routine H&E slides exist for every patient—plus post-pandemic demands for efficient, accessible tools amid oncology R&D spending pressures; ENLIGHT-DP eliminates sequencing barriers in low-resource areas, influencing ecosystem by empowering biopharma (faster trials, cost savings), oncologists (better outcomes), and patients (personalized matches).[2][5] Competitors like Perthera, BostonGene, and Strata Oncology focus on multi-omic matching but lack Pangea's gene-network depth and slide-based scalability, positioning Pangea to redefine standards and accelerate drug development in a market favoring adaptive, context-aware AI.[3]
Pangea Biomed stands at the forefront of making precision oncology universal, with ENLIGHT-DP poised for rapid adoption as pathology digitization surges. Next steps likely include broader clinical integrations, expanded validations for novel therapies, and partnerships to embed in global workflows—shaping trends like AI-biomarker efficiency and combo-drug optimization amid rising cancer incidence. Its influence could evolve from predictor to ecosystem enabler, slashing ineffective treatments and R&D waste, ultimately fulfilling its mission to democratize deep tumor intelligence for every patient.[4][5][7] This positions Pangea as a transformative force, turning precision oncology's promise into scalable reality.
Pangea Biomed has raised $12.0M across 2 funding rounds. Most recently, it raised $5.0M Seed in December 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2022 | $5.0M Seed | NFX, Vital Capital | |
| Apr 1, 2022 | $7.0M Seed | NFX, Vital Capital |